Sicart Associates’s Biogen BIIB Stock Holding History

Sicart Associates’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-1,400	Closed	-$397K	–	121
2020 Q3	$397K	Hold	1,400	–	–	0.12%	74
2020 Q2	$375K	Hold	1,400	–	–	0.12%	76
2020 Q1	$443K	Hold	1,400	–	–	0.17%	64
2019 Q4	$415K	Hold	1,400	–	–	0.14%	76
2019 Q3	$326K	Hold	1,400	–	–	0.11%	81
2019 Q2	$327K	Hold	1,400	–	–	0.13%	70
2019 Q1	$331K	Hold	1,400	–	–	0.14%	68
2018 Q4	$421K	Hold	1,400	–	–	0.2%	60
2018 Q3	$495K	Hold	1,400	–	–	0.24%	61
2018 Q2	$406K	Hold	1,400	–	–	0.21%	67
2018 Q1	$383K	Hold	1,400	–	–	0.23%	73
2017 Q4	$446K	Buy	+1,400	New	+$449K	0.24%	76
2017 Q1	–	Sell	-6,800	Closed	-$1.93M	–	91
2016 Q4	$1.93M	Buy	+6,800	New	+$2.02M	1.33%	25

Other funds holding BIIB

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Sicart Associates's BIIB Position: Q4 2020 in Review

Sicart Associates sold out of Biogen (BIIB) in Q4 2020, closing a stake of 1,400 shares — an estimated $397K sold.

Sicart Associates first reported a position in BIIB in Q4 2016 and held it in 13 quarters. The position peaked at $1.93M in Q4 2016. 1,062 funds tracked by Wall St. Rank hold BIIB as of Q4 2020.

Sicart Associates reported no remaining Biogen position as of Q4 2020 after selling out during the quarter.
Sicart Associates sold 1,400 Biogen shares in Q4 2020, an estimated $397K.
Sicart Associates first reported a position in Biogen in Q4 2016 and held it in 13 quarters.
Sicart Associates's Biogen position peaked at $1.93M in Q4 2016.
1,062 funds tracked by Wall St. Rank held Biogen as of Q4 2020.

Based on Sicart Associates's 13F filing for Q4 2020, filed 22 Jan 2021.